Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate

Drug Metabolism and Disposition

Volumn 35, Issue 8, 2007, Pages 1429-1434

  Mizuno, Naomi ^a   Takahashi, Tsuyoshi ^a   Iwase, Yumiko ^a   Kusuhara, Hiroyuki ^b   Niwa, Takuro ^a   Sugiyama, Yuichi ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NORPHENAZONE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG TRANSPORT; DRUG UPTAKE; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; KIDNEY TUBULE ABSORPTION; METABOLITE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIPYRINE; BIOLOGICAL TRANSPORT; CELL LINE; CELL PROLIFERATION; FREE RADICAL SCAVENGERS; GLUCURONIDES; HUMANS; KIDNEY; KIDNEY TUBULES, PROXIMAL; KINETICS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; SULFURIC ACID ESTERS; TRANSFECTION;

EID: 34547174404     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013912     Document Type: Article

References (41)

1. Brown GR (1993) Cephalosporin-probenecid drug interaction. Clin Pharmacokinet 24:289-300.
2. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, and Endou H (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286.
3. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, and Sweet DH (1999) The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56:570-580.
4. Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, and Jaffe HS (1995a) Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 39:2401-2405.
5. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, and Jaffe HS (1995b) Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 39:1247-1252.
6. Dalgard DW, Kota M, Miura M, and Tamura S (1997) Twenty six-week intravenous toxicity study of MCI-186 in beagle dogs with a recovery period of 5-week. Jpn Pharmacol Ther 25 (Suppl 7):S1589-S1614.
7. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, and Sugiyama Y (2004) Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65:162-174.
8. Edaravone Acute Infarction Study Group (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15:222-229.
9. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:393-395.
10. Enomoto A, Takeda M, Taki K, Takayama F, Noshiro R, Niwa T, and Endou H (2003) Interaction of human organic anion as well as cation transporters with indoxyl sulfate. Eur J Pharmacol 466:13-20.
11. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, et al. (2004) Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308:1021-1029.
12. Hasegawa M, Kusuhara H, Endou H, and Sugiyama Y (2003) Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J Pharmacol Exp Ther 305:1087-1097.
13. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, and Sugiyama Y (2002) Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther 300:746-753.
14. Hishida A (2007) Clinical analysis of 207 post-marketing surveillance-reported patients who developed renal disorders during or after treatment with edaravone. Clin Exp Nephrol, in press.
15. Ho ES, Lin DC, Mendel DB, and Cihlar T (2000) Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11:383-393.
16. Hosoyamada M, Sekine T, Kanai Y, and Endou H (1999) Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276:F122-F128.
17. Iwase Y, Ohyama N, Kondo H, Kifuji T, Fujisaki H, Takamatsu Y, Chen G, Silber P, Mutai M, and Tsutsui N (2004) Cytotoxic effects of edaravone in human renal cells. J Toxicol Sci 29:404.
18. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, and Endou H (1999) The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther 290:672-677.
19. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, and Endou E (2002) Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303:534-539.
20. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang X, Enomoto A, Piyachaturawat P, and Endou E (2004) Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharm Sci 94:197-202.
21. Komatsu T, Nakai H, Takamatsu Y, Morinaka Y, Watanabe K, Shinoda M, and Iida S (1996) Pharmacokinetic studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186): Metabolism in rats, dogs and human. Yakubutsudoutai 11:451-562.
22. Kusuhara H and Sugiyama Y (2002) Role of transporters in the tissue selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 78:43-54.
23. Lee W and Kim RB (2004) Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44:137-166.
24. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
25. Merino G, van Herwaaeden AE, Wagenaar E, Jonker JW, and Schinkel AH (2005) Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 67:1765-1771.
26. Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, and Sugiyama Y (2004) Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCC2) knockout mice. Drug Metabol Dispos 32:898-901.
27. Nozaki Y, Kusuhara H, Kondo T, Hasegawa M, Shiroyanagi Y, Nakazawa H, Okano T, and Sugiyama Y (2007) Characterization of the uptake of OAT1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther 321:362-369.
28. Okazaki S, Hatayama K, Tamura K, Mizuno H, and Miura M (1997) Twenty six-week intravenous toxicity study of MCI-186 in rats with a recovery period of 5-week. Jpn Pharmacol Ther 25 (Suppl 7):S1567-S1588.
29. Russel FG, Masereeuw R, and van Aubel RA (2002) Molecular aspects of renal anionic drug transport. Annu Rev Physiol 64:563-594.
30. Shibata H, Arai S, Izawa M, Murasaki M, Takamatsu Y, Izawa O, Takahashi C, and Tanaka M (1998) Phase I clinical study of MCI-186 (edaravone, 3-methyl-1-phenyl-2-pyrazolin-5-one) in healthy volunteers: safety and pharmacokinetics of single and multiple administrations. Jpn J Clin Pharmacol Ther 29:863-876.
31. Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, and Sugiyama Y (2005) Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharmacol Res 22:647-660.
32. Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, and Endou H (1999) Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int 56:2128-2136.
33. Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, Ibayashi S, and Iida M (2004) Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 221:11-17.
34. Ueo H, Motohashi H, Katsura T, and Inui K (2005) Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol 70:1104-1113.
35. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
36. Watanabe T, Morita I, Nishi H, and Murota S (1988) Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 33:81-87.
37. Watanabe T, Yuki S, Egawa M, and Nishi H (1994) Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 268:1597-1604.
38. Yamamoto M and Takamatsu Y (1997) Pharmacokinetic studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) protein binding and distribution to red blood cell. Jpn Pharmacol Ther 25:245-253.
39. Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito K, and Kogure K (1997) Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res 762:240-242.
40. Yamamoto Y, Kuwahara T, Watanabe K, and Watanabe K (1996) Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Report 2:333-338.
41. Yokota S, Kumagai Y, Uchiumi M, Isawa S, Murasaki M, Akimoto K, Iwamoto M, Yuasa T, and Iwano M (1997) A pharmacokinetic study of MCI-186, a novel drug for cerebrovascular disease in elderly and young healthy subjects. Jpn J Clin Pharmacol Ther 28:693-702.